Overview

Pathogenicity: Alzheimer's Disease : Pathogenic
ACMG/AMP Pathogenicity Criteria: PS3, PS4, PM1, PM2, PM5, PP1, PP2, PP3
Clinical Phenotype: Alzheimer's Disease
Position: (GRCh38/hg38):Chr14:73198100 A>C
Position: (GRCh37/hg19):Chr14:73664808 A>C
dbSNP ID: rs63750231
Coding/Non-Coding: Coding
DNA Change: Substitution
Expected RNA Consequence: Substitution
Expected Protein Consequence: Missense
Codon Change: GAA to GCA
Reference Isoform: PSEN1 Isoform 1 (467 aa)
Genomic Region: Exon 8

Findings

The E280A mutation is by far the most common cause of familial early onset Alzheimer’s disease, affecting hundreds of people. The majority of E280A carriers belong to a large kindred from the Colombian state of Antioquia, originally identified by the late Francisco Lopera in the early 1980s (Sep 2024 news). In fact, the mutation is often called the Paisa mutation in reference to the people of this region. The Colombian kindred is remarkable for a high level of participation in both longitudinal studies characterizing biomarker progression and pioneering prevention trials. Also, due to its large size, it has enabled the identification of genetic variants that confer protection against E280A, providing candidate therapeutic targets and insights into the mechanistic underpinnings of AD (see Genetic Modifiers below).

Currently, there are about 5,000 living members of the Colombian kindred spread among 25 families who live in a historically isolated region in the Andes Mountains. The pedigree spans five to seven generations, originating with a couple from the Basque region of Spain who settled in Colombia in the early 1700s (Lalli et al., 2014). Nearly half the living members of the kindred live in Medellín, the second-largest city in Colombia, with the majority of the others scattered in outlying villages. Of the 5,000 living members, it is estimated that nearly 1,000 carry the mutation, with about 400 confirmed carriers. Related carriers have been identified in other Colombian regions (Arango et al., 2001), and in other countries (Kwok et al., 1997). In addition, the mutation was identified in a Japanese family (FAD-Ok; Tanahashi et al., 1996). E280A was absent from the gnomAD variant database (gnomAD v2.1.1, July 2021).

Clinical Phenotype | Genetic Modifiers | Neuropathology | Early Structural, Functional, and Pathological Changes | Biological Effects | Research Models

Clinical Phenotype

Studies of the large Colombian kindred have revealed that mutation carriers typically develop memory deficits in the third decade of life, followed by progressive impairments in other cognitive domains, such as verbal fluency. Mild cognitive impairment sets in around age 45 and dementia by age 50. Although the vast majority of carriers develop dementia between age 45 and 50, a 30-year window has been documented, with rare cases experiencing onset as early as age 30 or as late as age 65. The mutation is, however, fully penetrant. The median duration from onset of dementia to death is approximately 10 years, ranging from nine to 12 years, with 59 being the median age at death (Acosta-Baena et al., 2011). There is no evidence of anticipation in subsequent generations. Homozygosity has been reported in this kindred. The age of onset for these individuals appears to be moderately accelerated relative to heterozygotes, although the sample is too small to reach statistical conclusions (Kosik et al., 2015).

The majority of E280A carriers present with symptoms fairly typical of AD, including progressive memory loss and changes in personality and behavior; however, there is phenotypic variability. For example, some patients also present with epilepsy, verbal impairment, and cerebellar ataxia. Specifically, mutation carriers present with memory impairment (100 percent), behavioral changes (94 percent), language impairment (e.g., aphasia, 81 percent), headache (73 percent), gait difficulties (65 percent), seizures and myoclonus (45 percent), and cerebellar signs and Parkinsonism (each 19 percent) (reviewed in Sepulveda-Falla et al., 2012).  Interestingly, gender appears to contribute to differences in cognition and neurodegeneration (Vila-Castelar et al., 2020; Fox-Fuller et al., 2021; Vila-Castelar et al., 2022; Martinez et al., 2022; Vila-Castelar et al., 2023). For example, neurodegeneration was reported to proceed faster in women than in men, but the rate did not predict cognitive performance (Vila-Castelar et al., 2023).

Several early signs of disease have been reported in carriers of this mutation. Cognitive decline, for example, has been detected 12 years before clinical onset of disease. Analysis of total CERAD scores, as well as individual scores for memory, language, and praxis, identified word-list recall as a particularly early indicator of decline (Aguirre-Acevedo et al., 2016). Even cognitively unimpaired E280A carriers score slightly lower on the Mini-Mental State Exam and memory tests than non-carriers (Rios-Romenets et al., 2020). Of note, awareness of memory function appears to decrease in the predementia stages, reaching anosognosia close to the age of mild cognitive impairment onset (Vannini et al., 2020). A review and analysis of published research identified modifications of verbal, semantic, episodic, and spatial memory as the most sensitive indicators of preclinical changes (Giudicessi et al., 2024).

Additional alterations foreshadow clinical disease. For example, severe headaches appear to be a common early symptom, typically occurring several years before dementia onset (Lopera et al., 1997). The risk of mental disorders in mutation carriers under the age of 30 was found to be similar to that of non-carriers (Villalba et al., 2019), but early depressive symptoms were associated with faster dementia progression (Acosta-Baena et al., 2023), and in cognitively unimpaired carriers, lower hippocampal volume was associated with greater depressive symptoms (Langella et al., 2023).

Given its extremely high penetrance and predictable age of onset, E280A has been instrumental in the identification of markers of AD as a function of carriers’ estimated years to clinical onset (for review see Fuller et al., 2019). In addition, carriers of this variant have been recruited in clinical trials. The Alzheimer Prevention Initiative, for example, relied on presymptomatic members of the Colombian E280A kindred to assess the effects of the therapeutic candidate crenezumab—a monoclonal antibody against oligomeric Aβ (Reiman et al., 2022).

Genetic Modifiers

Remarkably, two rare genetic variants—APOE R154S (R136S), a.k.a. as the Christchurch mutation, and RELN H3447R, a.k.a. Reelin-COLBOS—have been reported to confer what appears to be robust protection against the PSEN1 E280A mutation. The APOE Christchurch mutation was identified in homozygous form in a Colombian carrier of E280A who had only subtle short-term memory loss in her 70s (Nov 2019 news, Arboleda-Velasquez et al., 2019). PET imaging followed by postmortem analysis revealed an unusually high burden of amyloid-β plaque in her brain, with tau pathology restricted to medial temporal and occipital regions. Areas typically involved in AD, including the frontal cortex and hippocampus, were mostly spared, with neurons considered extremely vulnerable to tau-induced neurodegeneration—RORB+ excitatory neurons—remaining mostly intact (Sep 2022 conference news, Sepulveda-Falla et al., 2022, Henao-Restrepo et al., 2023).

In brain regions free of tau pathology, homeostatic astrocytes and microglia expressing genes involved in acute immune responses were observed. In contrast, the occipital cortex was laden with microglia expressing an inflammatory transcriptional profile. Also, cerebral amyloid angiopathy (CAA) was found in the amygdala and occipital cortex, which correlated with the extent of tau pathology and was in contrast to the widespread CAA seen in most E280A carriers. Glucose metabolism levels in areas associated with AD, such as the precuneus, were similar to those of age-matched, non-E280A carriers, as was the level of neurofilament light chain in plasma, an indicator of neuronal damage.

Although early studies suggested Christchurch heterozygosity is not  protective of Paisa-associated AD, a subsequent, larger study identified several signs of protection. In the original 2019 study, four Paisa carriers who carried one copy of Christchurch were reported to have developed cognitive impairment at ages similar to non-Christchurch carriers (Arboleda-Velazquez et al., 2019), and a subsequent study of 340 Paisa carriers, including 11 Christchurch heterozygotes, also failed to identify a protective effect (Cochran et al., 2023). However, a study of 1077 Paisa carriers, including 27 Christchurch heterozygotes, found the median age at onset of cognitive impairment was 52 years (95% CI, 51-58) in the Christchurch carriers compared with 47 years (95% CI, 47-49) in the Christchurch noncarriers (Quiroz et al, 2024, Aug 2023 conference news). Brain imaging of two of these individuals revealed relatively preserved metabolism in brain regions typically affected by AD compared with Christchurch noncarriers, and in one individual, 18F-flortaucipir PET imaging showed decreased tau pathology. In addition, post-mortem examination of brain samples from four carriers of both Christchurch and Paisa variants revealed reduced vascular amyloid pathology compared with carriers of only the Paisa variant.

The H3447R Reelin-COLBOS variant was identified in an E280A carrier who remained dementia-free 20 years after expected symptom onset (May 2023 news, Lopera et al., 2023). Like the homozygous APOE Christchurch carrier, he too had a high load of brain amyloid, with relatively few neurofibrillary tangles, particularly in the entorhinal cortex. The carrier of the Reelin variant had more phospho-tau, and microglia that were less activated than the Christchurch carrier. Both Christchurch and Reelin carriers had less ApoE in their cortical and hippocampal neurons than did other E280A carriers who had died in their 50s or 60s. The  sister of the Reelin carrier, who also carried the E280A and Reelin variants, showed signs of protection but she had co-morbidities that complicated the interpretation of her case.

The Reelin COLBOS variant enhances Reelin-Dab1 signaling which reduces tau phosphorylation. When crossed with a COLBOS knockin mice, P301L tauopathy mice did not develop their characteristic paralysis and had less p-tau205 in their hippocampi (Lopera et al., 2023, May 2023 news). Interestingly, increased mRNA and protein levels of several components of this signaling pathway have been identified in AD-susceptible brain regions in the early stages of sporadic AD (Ramsden et al., 2023), as well as in specific AD-vulnerable neuronal populations at baseline, absent AD pathology (Mathys et al., 2024).  

ApoE and Reelin both bind to the VLDL and APOEr2 receptors, the protective variants of both are near or in heparin-binding regions, and they may both modulate tau phosphorylation, possibly through GSK3β. However, their modes of protection could be very different, with Christchurch conferring resistance to AD pathology via widespread effects in the brain, and COLBOS conferring resilience via localized effects on specific brain regions and cell populations (Sepulveda-Falla, 2023). (For a more detailed description of potential mechanisms underlying Christchurch's protective effects see APOE R154S (R136S) Christchurch).

Additional loci that modify age of onset or rate of cognitive decline have been reported. Several dominant major genes (Vélez et al., 2013; Vélez et al., 2016a; Vélez et al., 2016b), as well as recessive variants appear to delay onset, up to 11 years, or accelerate onset, up to eight years (Vélez et al., 2019). The largest published study, including 340 mutation carriers, identified 13 variants, several in loci that included genes of known AD relevance such as CLU encoding the molecular chaperone clusterin, and genes involved in heparin sulfate biology and amyloid processing (Cochran et al., 2023). Moreover, a study of 62 Paisa carriers identified 172 variants associated with the rate of cognitive decline (Sepulveda-Falla et al., 2024). OR51B6, an olfactory receptor gene expressed in temporal cortical neurons, had the highest number of associated variants. 

Also of note, the APOE alleles—APOE2, APOE3 and APOE4—modify Paisa-associated AD. Although initial reports from small cohorts yielded conflicting results (Lendon et al., 1997; Pastor et al., 2003, Vélez et al., 2015), studies including hundreds of Paisa carriers showed that APOE genotype alters age-related cognitive decline (Langella et al., 2023) and plasma levels of the AD biomarker neurofilament light chain (Langella et al., 2024), with APOE4 accelerating these changes and APOE2 delaying them. 

Neuropathology

Those affected by the E280A mutation show neuropathology consistent with a diagnosis of AD, including severe brain atrophy, Aβ pathology, and hyperphosphorylated tau-related pathology. However, there are differences between E280A and sporadic AD pathology. In E280A AD, Aβ42 is particularly abundant in the cerebral cortex, hippocampus, cerebellum, midbrain, and basal ganglia. A study of frontal cortical tissue from 10 E280A carriers revealed an increased load of Aβ42 peptide and decreased loads of Aβ38 and Aβ43 peptides compared with cortical tissues from 10 individuals with sporadic AD (Dinkel et al., 2020). Also, cerebellar damage appears to be more common in Paisa carriers than in patients with sporadic AD (Lemere et al., 1996), with Aβ plaque deposition surfacing about a decade before the clinical onset of AD (Ghisays et al., 2021). Moreover, while decreases in basal forebrain volume and metabolism are characteristic of the preclinical and prodromal stages of sporadic AD, they do not surface early in E280A-associated AD (Teipel et al., 2024).

Comorbid pathologies are common in E280A carriers. Indeed, post-mortem brain tissues from 17 carriers described in a preprint, revealed that only 29 percent had exclusively AD pathology (Sepulveda-Falla et al., 2023).  Carriers had higher cerebral amyloid angiopathy (CAA) severity scores than either carriers of other PSEN1 mutations or non-carriers with early onset sporadic AD. Other cerebrovascular pathologies included atherosclerosis in the circle of Willis (19%), small vessel disease (25%), microinfarcts (4%) and cerebral microhemorrhages (2%). (The high percentage of athersoclerosis may be at least partially explained by environmental cardiovascular risk factors). In another study, amyloid-independent small vessel disease in the cortex and basal ganglia was found to be comparable to that seen in CADASIL patients, although often undetected by MRI (Littau et al., 2022). At least in the frontal cortex, E280A pathology appears to involve alterations in the gliovascular unit associated with hyperreactive astrocytes whose phenotype differs from that observed in astrocytes of patients with sporadic AD (Henao-Restrepo et al., 2023). 

Other neuropathologies have also been associated with E280A. For example, post-mortem tissues from 12 of 17 carriers (70 percent) had Lewy body disease, most being amygdala predominant, and 4 of 15 (27 percent) had TDP-43 pathology in the amygdala (Sepulveda-Falla et al., 2023). Moreover, transcriptional signatures of viral infection and inflammation in the olfactory bulb and tract have been reported (Bubak et al., 2023), and a subset of carriers suffering from seizures developed greater neuronal loss and hippocampal sclerosis similar to that found in epilepsy patients than patients without epileptic seizures (Velez-Pardo et al., 2004).

Early Structural, Functional, and Pathological Changes

Signs of structural and functional changes are consistent with the early signs of cognitive impairment discussed above in "Clinical Phenotype" (see Fuller et al., 2020 for review; Jul 2015 news). For example, hyperactivation within medial temporal lobe regions during the encoding of novel associations has been seen in young carriers, suggesting that carriers push their memory-forming circuitry harder to achieve equivalent performance (Quiroz et al., 2010; Quiroz et al., 2015). Presymptomatic reduction of hippocampal volume has also been reported (Fleisher et al., 2015). In addition, functional alterations in the precuneus have been detected at presymptomatic stages of disease (Fleisher et al., 2015; Ochoa et al., 2017), with a decline in locus coeruleus integrity foreshadowing tau pathology in this region (Jacobs et al., 2023). Interestingly, although robust reduction in cortical thickness was seen in carriers starting a decade before expected cognitive impairment, cortical thickness was increased in child carriers (Fox-Fuller et al., 2021). In another study, white matter hyperintensities increased prior to symptom onset and were tied to cognitive performance (Schoemaker et al., 2022).

Studies of Aβ and tau pathology using PET have also revealed early presymptomatic changes. For example, Aβ, as assessed by PiB-PET, was elevated in unimpaired carriers approximately 15 years prior to expected onset of mild cognitive impairment (Feb 2018 news; Quiroz et al., 2018). A longitudinal study tracking both amyloid and tau pathology confirmed this early Aβ accumulation, and mapped out subsequent pathological changes, including tau accumulation in the entorhinal cortex nine years prior to expected symptom onset, neocortical tau build-up and hippocampal atrophy six years prior to onset, and cognitive decline four years prior to onset (Sanchez et al., 2021). Of note, rates of tau accumulation among carriers were most rapid in the parietal neocortex, and tau levels in the entorhinal cortex predicted subsequent neocortical tau accumulation and cognitive decline.

Studies have also shown correlations between cognitive performance and amyloid and tau pathologies. For example, age-related elevation of Aβ in the striatum, which had a larger Aβ burden than the neocortex, was associated with lower memory scores and entorhinal tau pathology (Hanseeuw et al., 2019). Moreover, subjective cognitive decline, difficulties in recall tests, and impaired visual memory showed a close relationship with both cortical amyloid and tau pathology in the inferior temporal and entorhinal cortices (Gatchel et al., 2019; Guzmán-Vélez et al., 2020; Norton et al., 2020; Bocanegra et al., 2020). Neuroticisim in cognitively unimpaired carriers, on the other hand, was tied to entorhinal tau pathology, but not amyloid burden (Baena et al., 2021).

One study correlated tau and amyloid pathologies with patterns of connectivity in brain regions involved in memory and information-processing in non-demented E280A carriers (Guzmán-Vélez et al., 2022). The findings provide clues on the distinct ties the two pathologies have—both hypothesized to spread through functional networks—with the disruption of neural communication that results in cognitive impairment.

Presymptomatic changes in CSF and plasma biomarkers have also been examined. A reduction in Aβ42 and increases in total tau and phosphorylated tau were observed in the CSF of unimpaired mutation carriers (Fleisher et al., 2015; Jan 2015 news). All three changes were age-associated. Plasma Aβ42 levels were also found elevated, but not correlated with age. Of particular interest, plasma neurofilament light (NfL), was reported to distinguish mutation carriers from noncarriers as early as 22 years before expected disease onset (Aug 2019 conference news, Quiroz et al., 2020, May 2020 news, Masters, 2020), and higher plasma NfL levels were correlated with greater regional tau burden and worse cognition (Guzmán-Vélez et al., 2021). Moreover, plasma levels of p-tau217, a phosphorylated tau species whose plasma levels accurately discriminate between AD and other neurodegenerative disorders, distinguished mutation carriers 20 years prior to estimated onset of mild cognitive impairment (July 2020 news; Palmqvist et al., 2020) and were associated with the subsequent appearance of PET-detectable Aβ and tau deposits and reduced performance in memory tests (Aguillon et al., 2022). 

Biomarker differences have been detected in children as young as nine years old (see Fuller et al., 2019 for review; Jul 2015 news). Young mutation carriers had elevated plasma levels of Aβ1-42 and higher Aβ42:Aβ40 ratios, as well as changes in resting-state connectivity, and regional gray matter volumes. It is unknown if these differences are primarily neurodegenerative or neurodevelopmental (Quiroz et al., 2015; Jul 2015). 

Of note, some early alterations, such as changes in retinal thickness (Armstrong et al., 2021) and electroencephalography (EEG) patterns (García-Pretelt et al., 2022), are being examined for their potential as low-cost screening tools.

Biological Effects

In a variety of cell types, expression of mutant presenilin resulted in an increased level of secreted Aβ42, and an increased Aβ42/Aβ40 ratio (Murayama et al., 1999; Kaneko et al., 2007; Li et al., 2016, Soto-Mercado et al., 2020). Two of these studies suggested the mutation altered the specificity of the carboxypeptidase-like γ-cleavage, but spared the endoproteolytic ε-cleavage of APP and PSEN1 (Kaneko et al., 2007; Li et al., 2016). A subsequent cell-based study confirmed the increase in the Aβ42/Aβ40 ratio, but indicated Aβ42 production was decreased in cells expressing the mutant protein, as was production of total Aβ, Aβ38, and Aβ40 (Kakuda et al., 2021). Of note, this study revealed an increase in the toxic peptide Aβ43. A switch in the stepwise γ-cleavage pathway leading to production of this peptide may underlie or contribute to this effect. 

Consistent with the above observations, in vitro experiments with isolated proteins revealed an increase in the Aβ42/Aβ40 ratio, with reductions in both Aβ40 and Aβ42 production (Sun et al., 2017). Moreover, in vitro experiments testing the mutant’s γ-secretase activity at different temperatures showed the mutation increases enzyme-Aβn complex dissociation rates, enhancing the release of longer Aβ peptides (Szaruga et al., 2017; Jul 2017 news). 

More recently, two in-depth studies of the Aβ peptides produced by cells transfected with this variant revealed a deleterious effect, decreasing both the Aβ (37 + 38 + 40) / (42 + 43) and Aβ37/Aβ42 ratios compared with cells expressing wildtype PSEN1 (Apr 2022 news; Petit et al., 2022; Liu et al., 2022). Both ratios were reported to outperform the Aβ42/Aβ40 ratio as indicators of AD pathogenicity, with the former correlating with AD age at onset. Moreover, a follow-up study reported in a preprint, combined the Aβ (37 + 38 + 40) / (42 + 43) ratio with the commonly used Aβ42/Aβ40 ratio (a measure of the relative production of aggregation-prone Aβ) to yield a composite measure which reflects γ-secretase function as a percentage of wildtype activity (Schulz et al., 2023). This composite score (33.28 for E280A) was strongly associated, not only with age at onset, but with biomarker and cognitive trajectories.

As revealed by a cryo-electron microscopy study of the atomic structure of γ-secretase bound to an APP fragment, E280 appears to play a key role in stabilizing the hybrid β-sheet that forms between PSEN1 and APP in preparation for γ-secretase cleavage (Zhou et al., 2019; Jan 2019 news). The carboxylate side chain of E280 makes a bifurcated H-bond to the hydroxyl groups of Y154 and Y159, both from transmembrane domain 2 of PSEN1. These interactions are buttressed by two additional H-bonds from R278 to E280 and Y159. Based on these data, subsequent computational simulations suggest E280A reduces the stability of the protein and favors an open conformational state in which the substrate is held more loosely, resulting in imprecise cleavage and earlier release of longer Aβ peptides (Dehury et al., 2020).

Effects on other cellular functions have also been reported for this mutation. A comparison of single-nuclei transcriptomes in postmortem frontal cortices of E280A carriers with those of sporadic AD patients and controls, for example, indicated activation of chaperones and autophagy in astrocytes and neurons as distinctive of mutation carriers (Feb 2024 news; Almeida et al., 2024). The authors hypothesized this may reflect a homeostatic corrective response to the mutation's disruption of Psen1 folding. In contrast, Paisa microglia were less activated than those from sporadic AD patients, while several genes involved in immune responses to infection were  upregulated.

Additional effects on cellular physiology include reduced proteolytic processing of the Nav voltage-gated sodium channel in rodent neuroblastoma cells (Kim et al., 2014), as well as dysregulated mitochondrial function, autophagy, and calcium homeostasis (Rojas-Charry et al., 2020). Moreover, in cholinergic-like neurons derived from carrier mesenchymal stromal stem cells, the mutant was reported to increase tau phosphorylation at residues Ser202 and Thr205 (May 2020 news, Soto-Mercado et al., 2020). In addition, apoptosis markers were elevated accompanied by a disruption of mitochondrial potential and DNA fragmentation. Also in these cells, calcium flux was abnormal and acetylcholinesterase activity reduced. In glioblastoma cells, E280A has been reported to increase formation of mitochondria-associated endoplasmic reticulum membranes (MAMs), elevate production of mitochondrial superoxide, and disrupt mitochondrial membrane potential (Han et al., 2021). Moreover, in astrocytes derived from human induced pluripotent stem cells (iPSCs),  it altered metabolism and neurotransmitter transport (e.g., Salcedo et al., 2021, Salcedo et al., 2023).

Several in silico algorithms (SIFT, Polyphen-2, LRT, MutationTaster, MutationAssessor, FATHMM, PROVEAN, CADD, REVEL, and Reve in the VarCards database) predicted this variant is damaging (Xiao et al., 2021).

Research Models

Several cell models carrying this mutation have been created. Two isogenic iPSC lines, with either a homozygous or a heterozygous E280A mutation, have been generated using CRISPR-Cas9 technology to mutate PSEN1 in an iPSC line from a healthy individual (Frederiksen et al., 2019). Also, an iPSC line derived from a patient with early onset AD has been created (Vallejo-Diez et al., 2019). Using mesenchymal stromal stem cells from umbilical cords, researchers have also generated cholinergic-like neurons carrying the mutation (May 2020 news, Soto-Mercado et al., 2020). 

Of note, non-iPS cells derived from patients carrying the E280A mutation, including menstrual blood-derived menstrual stromal cells (MenSCs) and umbilical cord-derived Wharton Jelly's mesenchymal stromal cells (WJ-MSCs), have been examined as alternative cellular models (Mendivil-Perez et al., 2023). Cholinergic-like neurons and cerebroid spheroids derived from these alternative sources have been reported to reproduce AD neuropathology more efficiently and faster than neurosn derived from mutant iPSCs.  

Pathogenicity

Alzheimer's Disease : Pathogenic

This variant fulfilled the following criteria based on the ACMG/AMP guidelines. See a full list of the criteria in the Methods page.

Comments

1. • Alexei Koudinov
     
   • Posted: 11 Jul 2002
   • Paper: The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology.

   Please see the following letter in Science related to this article: Alzheimer's disease and amyloid beta protein Koudinov AR et al Science online,> Published 25 June 2002 [ Full Text ]

   View all comments by Alexei Koudinov

Make a Comment

To make a comment you must login or register.

References

News Citations

1. A Country Doctor, But Oh So Much More: Francisco Lopera, 73 12 Sep 2024
2. Can an ApoE Mutation Halt Alzheimer’s Disease? 4 Nov 2019
3. Does One Copy of the Christchurch ApoE Variant Slow Alzheimer’s? 12 Aug 2023
4. Reelin Variant Wards Off Dementia in Colombian Kindred Siblings 16 May 2023
5. Familial Alzheimer’s Gene Alters Children’s Brains 2 Jul 2015
6. In Familial Alzheimer’s, Tau Creeps into Cortex as Symptoms Show 14 Feb 2018
7. API Biomarker Data Mirror DIAN’s, Support Progression Models 16 Jan 2015
8. Colombian Cohort Delivers Data on Blood NfL 8 Aug 2019
9. In Colombian Alzheimer’s Kindred, Blood NfL Climbs 22 Years Before Symptoms 26 May 2020
10. Plasma p-Tau217 Set to Transform Alzheimer’s Diagnostics 29 Jul 2020
11. sAPP Binds GABA Receptor, and More News on APP 21 Jul 2017
12. Ratio of Short to Long Aβ Peptides: Better Handle on Alzheimer's than Aβ42/40? 20 Apr 2022
13. CryoEM γ-Secretase Structures Nail APP, Notch Binding 11 Jan 2019
14. Different Cellular Mechanisms in Familial and Sporadic Alzheimer’s? 29 Feb 2024
15. Umbilical Cord With Presenilin Mutation Births New Cell Model of Familial AD 27 May 2020

Mutations Citations

1. APOE R154S (Christchurch)
2. APOE C130R (ApoE4)
3. APOE R176C (ApoE2)

Paper Citations

1. Lalli MA, Cox HC, Arcila ML, Cadavid L, Moreno S, Garcia G, Madrigal L, Reiman EM, Arcos-Burgos M, Bedoya G, Brunkow ME, Glusman G, Roach JC, Hood L, Kosik KS, Lopera F. Origin of the PSEN1 E280A mutation causing early-onset Alzheimer's disease. Alzheimers Dement. 2014 Oct;10(5 Suppl):S277-S283.e10. Epub 2013 Nov 13 PubMed.
2. Arango D, Cruts M, Torres O, Backhovens H, Serrano ML, Villareal E, Montañes P, Matallana D, Cano C, Van Broeckhoven C, Jacquier M. Systematic genetic study of Alzheimer disease in Latin America: mutation frequencies of the amyloid beta precursor protein and presenilin genes in Colombia. Am J Med Genet. 2001 Oct 1;103(2):138-43. PubMed.
3. Kwok JB, Taddei K, Hallupp M, Fisher C, Brooks WS, Broe GA, Hardy J, Fulham MJ, Nicholson GA, Stell R, St George Hyslop PH, Fraser PE, Kakulas B, Clarnette R, Relkin N, Gandy SE, Schofield PR, Martins RN. Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype. Neuroreport. 1997 Apr 14;8(6):1537-42. PubMed.
4. Tanahashi H, Kawakatsu S, Kaneko M, Yamanaka H, Takahashi K, Tabira T. Sequence analysis of presenilin-1 gene mutation in Japanese Alzheimer's disease patients. Neurosci Lett. 1996 Nov 1;218(2):139-41. PubMed.
5. Acosta-Baena N, Sepulveda-Falla D, Lopera-Gómez CM, Jaramillo-Elorza MC, Moreno S, Aguirre-Acevedo DC, Saldarriaga A, Lopera F. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol. 2011 Mar;10(3):213-20. PubMed.
6. Kosik KS, Muñoz C, Lopez L, Arcila ML, García G, Madrigal L, Moreno S, Ríos Romenets S, Lopez H, Gutierrez M, Langbaum JB, Cho W, Suliman S, Tariot PN, Ho C, Reiman EM, Lopera F. Homozygosity of the autosomal dominant Alzheimer disease presenilin 1 E280A mutation. Neurology. 2015 Jan 13;84(2):206-8. Epub 2014 Dec 3 PubMed.
7. Sepulveda-Falla D, Glatzel M, Lopera F. Phenotypic Profile of Early-Onset Familial Alzheimer's Disease Caused by Presenilin-1 E280A Mutation. J Alzheimers Dis. 2012 Jan 1;32(1):1-12. PubMed.
8. Vila-Castelar C, Guzmán-Vélez E, Pardilla-Delgado E, Buckley RF, Bocanegra Y, Baena A, Fox-Fuller JT, Tirado V, Muñoz C, Giraldo M, Acosta-Baena N, Rios-Romenets S, Langbaum JB, Tariot PN, Lopera F, Reiman EM, Quiroz YT. Examining Sex Differences in Markers of Cognition and Neurodegeneration in Autosomal Dominant Alzheimer's Disease: Preliminary Findings from the Colombian Alzheimer's Prevention Initiative Biomarker Study. J Alzheimers Dis. 2020;77(4):1743-1753. PubMed.
9. Fox-Fuller JT, Artola A, Chen K, Pulsifer M, Ramirez D, Londono N, Aguirre-Acevedo DC, Vila-Castelar C, Baena A, Martinez J, Arboleda-Velasquez JF, Langbaum JB, Tariot PN, Reiman EM, Lopera F, Quiroz YT. Sex Differences in Cognitive Abilities Among Children With the Autosomal Dominant Alzheimer Disease Presenilin 1 E280A Variant From a Colombian Cohort. JAMA Netw Open. 2021 Aug 2;4(8):e2121697. PubMed.
10. Vila-Castelar C, Tariot PN, Sink KM, Clayton D, Langbaum JB, Thomas RG, Chen Y, Su Y, Chen K, Hu N, Giraldo-Chica M, Tobón C, Acosta-Baena N, Luna E, Londoño M, Ospina P, Tirado V, Muñoz C, Henao E, Bocanegra Y, Alvarez S, Rios-Romenets S, Ghisays V, Goradia D, Lee W, Luo J, Malek-Ahmadi MH, Protas HD, Lopera F, Reiman EM, Quiroz YT, API ADAD Colombia Trial Group. Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial. Alzheimers Dement. 2022 Feb 1; PubMed.
11. Martinez JE, Pardilla-Delgado E, Guzmán-Vélez E, Vila-Castelar C, Amariglio R, Gatchel J, Aguirre-Acevedo DC, Bocanegra Y, Baena A, Henao E, Tirado V, Muñoz C, Giraldo-Chica M, Lopera F, Quiroz YT. Subjective Cognitive Decline and its Relation to Verbal Memory and Sex in Cognitively Unimpaired Individuals from a Colombian Cohort with Autosomal-Dominant Alzheimer's Disease. J Int Neuropsychol Soc. 2022 Jul;28(6):541-549. Epub 2021 Jun 30 PubMed.
12. Vila-Castelar C, Chen Y, Langella S, Lopera F, Zetterberg H, Hansson O, Dage JL, Janelidzde S, Su Y, Chen K, Pluim McDowell C, Martinez JE, Ramirez-Gomez L, Garcia G, Aguillon D, Baena A, Giraldo-Chica M, Protas HD, Ghisays V, Rios-Romenets S, Tariot PN, Blennow K, Reiman EM, Quiroz YT. Sex differences in blood biomarkers and cognitive performance in individuals with autosomal dominant Alzheimer's disease. Alzheimers Dement. 2023 Sep;19(9):4127-4138. Epub 2023 Jun 6 PubMed.
13. Aguirre-Acevedo DC, Lopera F, Henao E, Tirado V, Muñoz C, Giraldo M, Bangdiwala SI, Reiman EM, Tariot PN, Langbaum JB, Quiroz YT, Jaimes F. Cognitive Decline in a Colombian Kindred With Autosomal Dominant Alzheimer Disease: A Retrospective Cohort Study. JAMA Neurol. 2016 Apr;73(4):431-8. PubMed.
14. Rios-Romenets S, Lopera F, Sink KM, Hu N, Lian Q, Guthrie H, Smith J, Cho W, Mackey H, Langbaum JB, Thomas RG, Giraldo-Chica M, Tobon C, Acosta-Baena N, Muñoz C, Ospina P, Tirado V, Henao E, Bocanegra Y, Chen K, Su Y, Goradia D, Thiyyagura P, VanGilder PS, Luo J, Ghisays V, Lee W, Malek-Ahmadi MH, Protas HD, Chen Y, Quiroz YT, Reiman EM, Tariot PN, the API ADAD Colombia Trial Group. Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial. Alzheimers Dement. 2020 Jul;16(7):1023-1030. Epub 2020 May 17 PubMed.
15. Vannini P, Hanseeuw BJ, Gatchel JR, Sikkes SA, Alzate D, Zuluaga Y, Moreno S, Mendez L, Baena A, Ospina-Lopera P, Tirado V, Henao E, Acosta-Baena N, Giraldo M, Lopera F, Quiroz YT. Trajectory of Unawareness of Memory Decline in Individuals With Autosomal Dominant Alzheimer Disease. JAMA Netw Open. 2020 Dec 1;3(12):e2027472. PubMed.
16. Giudicessi A, McDowell CP, Martinez JE, Baena A, Vila-Castelar C, Norton D, Aguirre-Acevedo DC, Tirado V, Bocanegra Y, Guzman-Velez E, Lopera F, Cronin-Golomb A, Quiroz YT. Cognitive Outcomes in Autosomal-Dominant Alzheimer's Disease: A Comprehensive Review from a Colombian Kindred with the Presenilin-1 E280A Mutation. J Alzheimers Dis. 2024;101(2):397-415. PubMed.
17. Lopera F, Ardilla A, Martínez A, Madrigal L, Arango-Viana JC, Lemere CA, Arango-Lasprilla JC, Hincapíe L, Arcos-Burgos M, Ossa JE, Behrens IM, Norton J, Lendon C, Goate AM, Ruiz-Linares A, Rosselli M, Kosik KS. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA. 1997 Mar 12;277(10):793-9. PubMed.
18. Villalba AC, García J, Ramos C, Cuastumal AR, Aguillón D, Aguirre-Acevedo DC, Madrigal L, Lopera F. Mental Disorders in Young Adults from Families with the Presenilin-1 Gene Mutation E280A in the Preclinical Stage of Alzheimer's Disease. J Alzheimers Dis Rep. 2019 Aug 29;3(1):241-250. PubMed.
19. Acosta-Baena N, Lopera-Gómez CM, Jaramillo-Elorza MC, Velilla-Jiménez L, Villegas-Lanau CA, Sepúlveda-Falla D, Arcos-Burgos M, Lopera F. Early Depressive Symptoms Predict Faster Dementia Progression in Autosomal-Dominant Alzheimer's Disease. J Alzheimers Dis. 2023;92(3):911-923. PubMed.
20. Langella S, Lopera F, Baena A, Fox-Fuller JT, Munera D, Martinez JE, Giudicessi A, Vannini P, Hanseeuw BJ, Marshall GA, Quiroz YT, Gatchel JR. Depressive symptoms and hippocampal volume in autosomal dominant Alzheimer's disease. Alzheimers Dement. 2024 Feb;20(2):986-994. Epub 2023 Oct 14 PubMed.
21. Fuller JT, Cronin-Golomb A, Gatchel JR, Norton DJ, Guzmán-Vélez E, Jacobs HI, Hanseeuw B, Pardilla-Delgado E, Artola A, Baena A, Bocanegra Y, Kosik KS, Chen K, Tariot PN, Johnson K, Sperling RA, Reiman EM, Lopera F, Quiroz YT. Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred. J Prev Alzheimers Dis. 2019;6(2):112-120. PubMed.
22. Reiman EM, Pruzin JJ, Rios-Romenets S, Brown C, Giraldo M, Acosta-Baena N, Tobon C, Hu N, Chen Y, Ghisays V, Enos J, Goradia DD, Lee W, Luo J, Malek-Ahmadi M, Protas H, Thomas RG, Chen K, Su Y, Boker C, Mastroeni D, Alvarez S, Quiroz YT, Langbaum JB, Sink KM, Lopera F, Tariot PN, and the API ADAD Colombia Trial Group. A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial. Alzheimers Dement. 2023 May;19(5):1938-1946. Epub 2022 Nov 14 PubMed.
23. Arboleda-Velasquez JF, Lopera F, O'Hare M, Delgado-Tirado S, Marino C, Chmielewska N, Saez-Torres KL, Amarnani D, Schultz AP, Sperling RA, Leyton-Cifuentes D, Chen K, Baena A, Aguillon D, Rios-Romenets S, Giraldo M, Guzmán-Vélez E, Norton DJ, Pardilla-Delgado E, Artola A, Sanchez JS, Acosta-Uribe J, Lalli M, Kosik KS, Huentelman MJ, Zetterberg H, Blennow K, Reiman RA, Luo J, Chen Y, Thiyyagura P, Su Y, Jun GR, Naymik M, Gai X, Bootwalla M, Ji J, Shen L, Miller JB, Kim LA, Tariot PN, Johnson KA, Reiman EM, Quiroz YT. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019 Nov;25(11):1680-1683. Epub 2019 Nov 4 PubMed.
24. Sepulveda-Falla D, Sanchez JS, Almeida MC, Boassa D, Acosta-Uribe J, Vila-Castelar C, Ramirez-Gomez L, Baena A, Aguillon D, Villalba-Moreno ND, Littau JL, Villegas A, Beach TG, White CL 3rd, Ellisman M, Krasemann S, Glatzel M, Johnson KA, Sperling RA, Reiman EM, Arboleda-Velasquez JF, Kosik KS, Lopera F, Quiroz YT. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. Acta Neuropathol. 2022 Sep;144(3):589-601. Epub 2022 Jul 15 PubMed.
25. Henao-Restrepo J, López-Murillo C, Valderrama-Carmona P, Orozco-Santa N, Gomez J, Gutiérrez-Vargas J, Moraga R, Toledo J, Littau JL, Härtel S, Arboleda-Velásquez JF, Sepulveda-Falla D, Lopera F, Cardona-Gómez GP, Villegas A, Posada-Duque R. Gliovascular alterations in sporadic and familial Alzheimer's disease: APOE3 Christchurch homozygote glioprotection. Brain Pathol. 2022 Sep 21;:e13119. PubMed.
26. Cochran JN, Acosta-Uribe J, Esposito BT, Madrigal L, Aguillón D, Giraldo MM, Taylor JW, Bradley J, Fulton-Howard B, Andrews SJ, Acosta-Baena N, Alzate D, Garcia GP, Piedrahita F, Lopez HE, Anderson AG, Rodriguez-Nunez I, Roberts K, Dominantly Inherited Alzheimer Network, Absher D, Myers RM, Beecham GW, Reitz C, Rizzardi LF, Fernandez MV, Goate AM, Cruchaga C, Renton AE, Lopera F, Kosik KS. Genetic associations with age at dementia onset in the PSEN1 E280A Colombian kindred. Alzheimers Dement. 2023 Sep;19(9):3835-3847. Epub 2023 Mar 23 PubMed.
27. Quiroz YT, Aguillon D, Aguirre-Acevedo DC, Vasquez D, Zuluaga Y, Baena AY, Madrigal L, Hincapié L, Sanchez JS, Langella S, Posada-Duque R, Littau JL, Villalba-Moreno ND, Vila-Castelar C, Ramirez Gomez L, Garcia G, Kaplan E, Rassi Vargas S, Ossa JA, Valderrama-Carmona P, Perez-Corredor P, Krasemann S, Glatzel M, Kosik KS, Johnson K, Sperling RA, Reiman EM, Sepulveda-Falla D, Lopera F, Arboleda-Velasquez JF. APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease. N Engl J Med. 2024 Jun 20;390(23):2156-2164. PubMed.
28. Lopera F, Marino C, Chandrahas AS, O'Hare M, Villalba-Moreno ND, Aguillon D, Baena A, Sanchez JS, Vila-Castelar C, Ramirez Gomez L, Chmielewska N, Oliveira GM, Littau JL, Hartmann K, Park K, Krasemann S, Glatzel M, Schoemaker D, Gonzalez-Buendia L, Delgado-Tirado S, Arevalo-Alquichire S, Saez-Torres KL, Amarnani D, Kim LA, Mazzarino RC, Gordon H, Bocanegra Y, Villegas A, Gai X, Bootwalla M, Ji J, Shen L, Kosik KS, Su Y, Chen Y, Schultz A, Sperling RA, Johnson K, Reiman EM, Sepulveda-Falla D, Arboleda-Velasquez JF, Quiroz YT. Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man. Nat Med. 2023 May;29(5):1243-1252. Epub 2023 May 15 PubMed.
29. Ramsden CE, Zamora D, Horowitz MS, Jahanipour J, Calzada E, Li X, Keyes GS, Murray HC, Curtis MA, Faull RM, Sedlock A, Maric D. ApoER2-Dab1 disruption as the origin of pTau-associated neurodegeneration in sporadic Alzheimer's disease. Acta Neuropathol Commun. 2023 Dec 13;11(1):197. PubMed.
30. Mathys H, Boix CA, Akay LA, Xia Z, Davila-Velderrain J, Ng AP, Jiang X, Abdelhady G, Galani K, Mantero J, Band N, James BT, Babu S, Galiana-Melendez F, Louderback K, Prokopenko D, Tanzi RE, Bennett DA, Tsai LH, Kellis M. Single-cell multiregion dissection of Alzheimer's disease. Nature. 2024 Aug;632(8026):858-868. Epub 2024 Jul 24 PubMed.
31. Sepulveda-Falla D. Resistant and Resilient mutations in protection against familial Alzheimer's disease: learning from nature. Mol Neurodegener. 2023 Jun 1;18(1):36. PubMed.
32. Vélez JI, Chandrasekharappa SC, Henao E, Martinez AF, Harper U, Jones M, Solomon BD, Lopez L, Garcia G, Aguirre-Acevedo DC, Acosta-Baena N, Correa JC, Lopera-Gómez CM, Jaramillo-Elorza MC, Rivera D, Kosik KS, Schork NJ, Swanson JM, Lopera F, Arcos-Burgos M. Pooling/bootstrap-based GWAS (pbGWAS) identifies new loci modifying the age of onset in PSEN1 p.Glu280Ala Alzheimer's disease. Mol Psychiatry. 2012 Jun 19; PubMed.
33. Vélez JI, Lopera F, Patel HR, Johar AS, Cai Y, Rivera D, Tobón C, Villegas A, Sepulveda-Falla D, Lehmann SG, Easteal S, Mastronardi CA, Arcos-Burgos M. Mutations modifying sporadic Alzheimer's disease age of onset. Am J Med Genet B Neuropsychiatr Genet. 2016 Dec;171(8):1116-1130. Epub 2016 Aug 30 PubMed.
34. Vélez JI, Rivera D, Mastronardi CA, Patel HR, Tobón C, Villegas A, Cai Y, Easteal S, Lopera F, Arcos-Burgos M. A Mutation in DAOA Modifies the Age of Onset in PSEN1 E280A Alzheimer's Disease. Neural Plast. 2016;2016:9760314. Epub 2016 Jan 5 PubMed.
35. Vélez JI, Lopera F, Silva CT, Villegas A, Espinosa LG, Vidal OM, Mastronardi CA, Arcos-Burgos M. Familial Alzheimer's Disease and Recessive Modifiers. Mol Neurobiol. 2020 Feb;57(2):1035-1043. Epub 2019 Oct 29 PubMed.
36. Sepulveda-Falla D, Vélez JI, Acosta-Baena N, Baena A, Moreno S, Krasemann S, Lopera F, Mastronardi CA, Arcos-Burgos M. Genetic modifiers of cognitive decline in PSEN1 E280A Alzheimer's disease. Alzheimers Dement. 2024 Apr;20(4):2873-2885. Epub 2024 Mar 7 PubMed.
37. Lendon CL, Martinez A, Behrens IM, Kosik KS, Madrigal L, Norton J, Neuman R, Myers A, Busfield F, Wragg M, Arcos M, Arango Viana JC, Ossa J, Ruiz A, Goate AM, Lopera F. E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles. Hum Mutat. 1997;10(3):186-95. PubMed.
38. Pastor P, Roe CM, Villegas A, Bedoya G, Chakraverty S, García G, Tirado V, Norton J, Ríos S, Martínez M, Kosik KS, Lopera F, Goate AM. Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol. 2003 Aug;54(2):163-9. PubMed.
39. Vélez JI, Lopera F, Sepulveda-Falla D, Patel HR, Johar AS, Chuah A, Tobón C, Rivera D, Villegas A, Cai Y, Peng K, Arkell R, Castellanos FX, Andrews SJ, Silva Lara MF, Creagh PK, Easteal S, de Leon J, Wong ML, Licinio J, Mastronardi CA, Arcos-Burgos M. APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer's disease. Mol Psychiatry. 2015 Dec 1; PubMed.
40. Langella S, Barksdale NG, Vasquez D, Aguillon D, Chen Y, Su Y, Acosta-Baena N, Acosta-Uribe J, Baena AY, Garcia-Ospina G, Giraldo-Chica M, Tirado V, Muñoz C, Ríos-Romenets S, Guzman-Martínez C, Oliveira G, Yang HS, Vila-Castelar C, Pruzin JJ, Ghisays V, Arboleda-Velasquez JF, Kosik KS, Reiman EM, Lopera F, Quiroz YT. Effect of apolipoprotein genotype and educational attainment on cognitive function in autosomal dominant Alzheimer's disease. Nat Commun. 2023 Aug 23;14(1):5120. PubMed.
41. Langella S, Bonta K, Chen Y, Su Y, Vasquez D, Aguillon D, Acosta-Baena N, Baena AY, Garcia-Ospina G, Giraldo-Chica M, Tirado V, Muñoz C, Ríos-Romenets S, Guzman-Martínez C, Pruzin JJ, Ghisays V, Arboleda-Velasquez JF, Kosik KS, Tariot PN, Reiman EM, Lopera F, Quiroz YT. Impact of APOE ε4 and ε2 on plasma neurofilament light chain and cognition in autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2024 Oct 1;16(1):208. PubMed.
42. Dinkel F, Trujillo-Rodriguez D, Villegas A, Streffer J, Mercken M, Lopera F, Glatzel M, Sepulveda-Falla D. Decreased Deposition of Beta-Amyloid 1-38 and Increased Deposition of Beta-Amyloid 1-42 in Brain Tissue of Presenilin-1 E280A Familial Alzheimer's Disease Patients. Front Aging Neurosci. 2020;12:220. Epub 2020 Jul 28 PubMed.
43. Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, Yamaguchi H, Ruiz A, Martinez A, Madrigal L, Hincapie L, Arango JC, Anthony DC, Koo EH, Goate AM, Selkoe DJ, Arango JC. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med. 1996 Oct;2(10):1146-50. PubMed.
44. Ghisays V, Lopera F, Goradia DD, Protas HD, Malek-Ahmadi MH, Chen Y, Devadas V, Luo J, Lee W, Baena A, Bocanegra Y, Guzmán-Vélez E, Pardilla-Delgado E, Vila-Castelar C, Fox-Fuller JT, Hu N, Clayton D, Thomas RG, Alvarez S, Espinosa A, Acosta-Baena N, Giraldo MM, Rios-Romenets S, Langbaum JB, Chen K, Su Y, Tariot PN, Quiroz YT, Reiman EM, API ADAD Colombia Trial Group. PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers. Neuroimage Clin. 2021;31:102749. Epub 2021 Jul 4 PubMed.
45. Teipel S, Grazia A, Dyrba M, Grothe MJ, Pomara N. Basal forebrain volume and metabolism in carriers of the Colombian mutation for autosomal dominant Alzheimer's disease. Sci Rep. 2024 May 17;14(1):11268. PubMed.
46. Sepulveda-Falla D, VillegasLanau CA, White C, Serrano GE, AcostaUribe J, MejiaCupajita B, Villalba-Moreno ND, Lu P, Glatzel M, Kofler JK, Ghetti B, Frosch MP, LoperaRestrepo F, Kosik KS, Beach TG. Comorbidities in Early-Onset Sporadic versus Presenilin-1 Mutation-Associated Alzheimers Disease Dementia: Evidence for Dependency on Alzheimers Disease Neuropathological Changes. 2023 Aug 17 10.1101/2023.08.14.23294081 (version 1) medRxiv.
47. Littau JL, Velilla L, Hase Y, Villalba-Moreno ND, Hagel C, Drexler D, Osorio Restrepo S, Villegas A, Lopera F, Vargas S, Glatzel M, Krasemann S, Quiroz YT, Arboleda-Velasquez JF, Kalaria R, Sepulveda-Falla D. Evidence of beta amyloid independent small vessel disease in familial Alzheimer's disease. Brain Pathol. 2022 Nov;32(6):e13097. Epub 2022 Jun 13 PubMed.
48. Bubak AN, Merle L, Niemeyer CS, Baxter BD, Gentile Polese A, Ramakrishnan V, Gomez J, Madrigal L, Villegas-Lanau A, Lopera F, Macklin W, Frietze S, Nagel MA, Restrepo D. Signatures for viral infection and inflammation in the proximal olfactory system in familial Alzheimer's disease. Neurobiol Aging. 2023 Mar;123:75-82. Epub 2022 Dec 13 PubMed.
49. Velez-Pardo C, Arellano JI, Cardona-Gomez P, Jimenez Del Rio M, Lopera F, De Felipe J. CA1 hippocampal neuronal loss in familial Alzheimer's disease presenilin-1 E280A mutation is related to epilepsy. Epilepsia. 2004 Jul;45(7):751-6. PubMed.
50. Quiroz YT, Budson AE, Celone K, Ruiz A, Newmark R, Castrillón G, Lopera F, Stern CE. Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Ann Neurol. 2010 Dec;68(6):865-75. PubMed.
51. Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gutierrez Gomez M, Langois CM, Langbaum JB, Roontiva A, Thiyyagura P, Lee W, Ayutyanont N, Lopez L, Moreno S, Muñoz C, Tirado V, Acosta-Baena N, Fagan AM, Giraldo M, Garcia G, Huentelman MJ, Tariot PN, Lopera F, Reiman EM. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol. 2015 Mar;72(3):316-24. PubMed.
52. Ochoa JF, Alonso JF, Duque JE, Tobón CA, Baena A, Lopera F, Mañanas MA, Hernández AM. Precuneus Failures in Subjects of the PSEN1 E280A Family at Risk of Developing Alzheimer's Disease Detected Using Quantitative Electroencephalography. J Alzheimers Dis. 2017;58(4):1229-1244. PubMed.
53. Jacobs HI, Becker JA, Kwong K, Munera D, Ramirez-Gomez L, Engels-Domínguez N, Sanchez JS, Vila-Castelar C, Baena A, Sperling RA, Johnson KA, Lopera F, Quiroz YT. Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease. Alzheimers Dement. 2023 Jan;19(1):169-180. Epub 2022 Mar 17 PubMed.
54. Fox-Fuller JT, Torrico-Teave H, d'Oleire Uquillas F, Chen K, Su Y, Chen Y, Brickhouse M, Sanchez JS, Aguero C, Jacobs HI, Hampton O, Guzmán-Vélez E, Vila-Castelar C, Aguirre-Acevedo DC, Baena A, Artola A, Martinez J, Pluim CF, Alvarez S, Ochoa-Escudero M, Reiman EM, Sperling RA, Lopera F, Johnson KA, Dickerson BC, Quiroz YT. Cortical thickness across the lifespan in a Colombian cohort with autosomal-dominant Alzheimer's disease: A cross-sectional study. Alzheimers Dement (Amst). 2021;13(1):e12233. Epub 2021 Sep 14 PubMed.
55. Schoemaker D, Zanon Zotin MC, Chen K, Igwe KC, Vila-Castelar C, Martinez J, Baena A, Fox-Fuller JT, Lopera F, Reiman EM, Brickman AM, Quiroz YT. White matter hyperintensities are a prominent feature of autosomal dominant Alzheimer's disease that emerge prior to dementia. Alzheimers Res Ther. 2022 Jun 29;14(1):89. PubMed.
56. Quiroz YT, Sperling RA, Norton DJ, Baena A, Arboleda-Velasquez JF, Cosio D, Schultz A, Lapoint M, Guzman-Velez E, Miller JB, Kim LA, Chen K, Tariot PN, Lopera F, Reiman EM, Johnson KA. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. JAMA Neurol. 2018 May 1;75(5):548-556. PubMed.
57. Sanchez JS, Hanseeuw BJ, Lopera F, Sperling RA, Baena A, Bocanegra Y, Aguillon D, Guzmán-Vélez E, Pardilla-Delgado E, Ramirez-Gomez L, Vila-Castelar C, Martinez JE, Fox-Fuller JT, Ramos C, Ochoa-Escudero M, Alvarez S, Jacobs HI, Schultz AP, Gatchel JR, Becker JA, Katz SR, Mayblyum DV, Price JC, Reiman EM, Johnson KA, Quiroz YT. Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study. Alzheimers Res Ther. 2021 Jan 15;13(1):27. PubMed.
58. Hanseeuw BJ, Lopera F, Sperling RA, Norton DJ, Guzman-Velez E, Baena A, Pardilla-Delgado E, Schultz AP, Gatchel J, Jin D, Chen K, Reiman EM, Johnson KA, Quiroz YT. Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimer's disease. Alzheimers Res Ther. 2019 Feb 4;11(1):17. PubMed.
59. Gatchel JR, Lopera F, Norton DJ, Baena A, Guzman-Velez E, Sanchez JS, d'Oleire Uquillas F, Schultz A, Vannini P, Artola A, Amariglio RE, Rentz DM, Tariot PN, Reiman EM, Johnson KA, Sperling RA, Marshall GA, Quiroz YT. Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):330-332. Epub 2019 Dec 24 PubMed.
60. Guzmán-Vélez E, Martínez J, Papp K, Baena A, Vila-Castelar C, Artola A, Schultz AP, Bocanegra Y, Sanchez J, Rentz D, Tariot PN, Reiman EM, Sperling R, Johnson KA, Lopera F, Quiroz YT. Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. Neurology. 2020 Sep 8;95(10):e1312-e1321. Epub 2020 Jul 1 PubMed.
61. Norton DJ, Parra MA, Sperling RA, Baena A, Guzman-Velez E, Jin DS, Andrea N, Khang J, Schultz A, Rentz DM, Pardilla-Delgado E, Fuller J, Johnson K, Reiman EM, Lopera F, Quiroz YT. Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2020 Aug 21;12(1):99. PubMed.
62. Bocanegra Y, Fox-Fuller JT, Baena A, Guzmán-Vélez E, Vila-Castelar C, Martínez J, Torrico-Teave H, Lopera F, Quiroz YT. Association Between Visual Memory and In Vivo Amyloid and Tau Pathology in Preclinical Autosomal Dominant Alzheimer's Disease. J Int Neuropsychol Soc. 2021 Jan;27(1):47-55. Epub 2020 Aug 7 PubMed.
63. Baena A, Bocanegra Y, Torres V, Vila-Castelar C, Guzmán-Vélez E, Fox-Fuller JT, Gatchel JR, Sánchez J, Pluim CF, Ramirez-Gómez L, Martínez J, Pineda D, Lopera F, Quiroz YT. Neuroticism Is Associated with Tau Pathology in Cognitively Unimpaired Individuals with Autosomal Dominant Alzheimer's Disease. J Alzheimers Dis. 2021;82(4):1809-1822. PubMed.
64. Guzmán-Vélez E, Diez I, Schoemaker D, Pardilla-Delgado E, Vila-Castelar C, Fox-Fuller JT, Baena A, Sperling RA, Johnson KA, Lopera F, Sepulcre J, Quiroz YT. Amyloid-β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer's disease. Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2113641119. Epub 2022 Apr 5 PubMed.
65. Quiroz YT, Zetterberg H, Reiman EM, Chen Y, Su Y, Fox-Fuller JT, Garcia G, Villegas A, Sepulveda-Falla D, Villada M, Arboleda-Velasquez JF, Guzmán-Vélez E, Vila-Castelar C, Gordon BA, Schultz SA, Protas HD, Ghisays V, Giraldo M, Tirado V, Baena A, Munoz C, Rios-Romenets S, Tariot PN, Blennow K, Lopera F. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. Lancet Neurol. 2020 Jun;19(6):513-521. Epub 2020 May 26 PubMed.
66. Masters CL. Major risk factors for Alzheimer's disease: age and genetics. Lancet Neurol. 2020 Jun;19(6):475-476. Epub 2020 May 26 PubMed.
67. Guzmán-Vélez E, Zetterberg H, Fox-Fuller JT, Vila-Castelar C, Sanchez JS, Baena A, Garcia-Ospina G, Aguillon D, Pardilla-Delgado E, Gatchel JR, Sperling RA, Johnson K, Reiman EM, Blennow K, Lopera F, Quiroz YT. Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease. Alzheimers Dement. 2021 May;17(5):813-821. Epub 2021 Feb 1 PubMed.
68. Aguillon D, Langella S, Chen Y, Sanchez JS, Su Y, Vila-Castelar C, Vasquez D, Zetterberg H, Hansson O, Dage JL, Janelidze S, Chen K, Fox-Fuller JT, Aduen P, Martinez JE, Garcia G, Baena A, Guzman C, Johnson KA, Sperling RA, Blennow K, Reiman EM, Lopera F, Quiroz YT. Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease. Alzheimers Dement. 2023 Jun;19(6):2585-2594. Epub 2022 Dec 26 PubMed.
69. Quiroz YT, Schultz AP, Chen K, Protas HD, Brickhouse M, Fleisher AS, Langbaum JB, Thiyyagura P, Fagan AM, Shah AR, Muniz M, Arboleda-Velasquez JF, Munoz C, Garcia G, Acosta-Baena N, Giraldo M, Tirado V, Ramírez DL, Tariot PN, Dickerson BC, Sperling RA, Lopera F, Reiman EM. Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study. JAMA Neurol. 2015 Aug;72(8):912-9. PubMed.
70. Armstrong GW, Kim LA, Vingopoulos F, Park JY, Garg I, Kasetty M, Silverman RF, Zeng R, Douglas VP, Lopera F, Baena A, Giraldo M, Norton D, Cronin-Golomb A, Arboleda-Velasquez JF, Quiroz YT, Miller JB. Retinal Imaging Findings in Carriers With PSEN1-Associated Early-Onset Familial Alzheimer Disease Before Onset of Cognitive Symptoms. JAMA Ophthalmol. 2021 Jan 1;139(1):49-56. PubMed.
71. García-Pretelt FJ, Suárez-Relevo JX, Aguillon-Niño DF, Lopera-Restrepo FJ, Ochoa-Gómez JF, Tobón-Quintero CA. Automatic Classification of Subjects of the PSEN1-E280A Family at Risk of Developing Alzheimer's Disease Using Machine Learning and Resting State Electroencephalography. J Alzheimers Dis. 2022;87(2):817-832. PubMed.
72. Murayama O, Tomita T, Nihonmatsu N, Murayama M, Sun X, Honda T, Iwatsubo T, Takashima A. Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. Neurosci Lett. 1999 Apr 9;265(1):61-3. PubMed.
73. Kaneko H, Kakita A, Kasuga K, Nozaki H, Ishikawa A, Miyashita A, Kuwano R, Ito G, Iwatsubo T, Takahashi H, Nishizawa M, Onodera O, Sisodia SS, Ikeuchi T. Enhanced accumulation of phosphorylated alpha-synuclein and elevated beta-amyloid 42/40 ratio caused by expression of the presenilin-1 deltaT440 mutant associated with familial Lewy body disease and variant Alzheimer's disease. J Neurosci. 2007 Nov 28;27(48):13092-7. PubMed.
74. Li N, Liu K, Qiu Y, Ren Z, Dai R, Deng Y, Qing H. Effect of Presenilin Mutations on APP Cleavage; Insights into the Pathogenesis of FAD. Front Aging Neurosci. 2016;8:51. Epub 2016 Mar 11 PubMed.
75. Soto-Mercado V, Mendivil-Perez M, Velez-Pardo C, Lopera F, Jimenez-Del-Rio M. Cholinergic-like neurons carrying PSEN1 E280A mutation from familial Alzheimer's disease reveal intraneuronal sAPPβ fragments accumulation, hyperphosphorylation of TAU, oxidative stress, apoptosis and Ca2+ dysregulation: Therapeutic implications. PLoS One. 2020;15(5):e0221669. Epub 2020 May 21 PubMed.
76. Kakuda N, Takami M, Okochi M, Kasuga K, Ihara Y, Ikeuchi T. Switched Aβ43 generation in familial Alzheimer's disease with presenilin 1 mutation. Transl Psychiatry. 2021 Nov 3;11(1):558. PubMed.
77. Sun L, Zhou R, Yang G, Shi Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase. Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E476-E485. Epub 2016 Dec 5 PubMed.
78. Szaruga M, Munteanu B, Lismont S, Veugelen S, Horré K, Mercken M, Saido TC, Ryan NS, De Vos T, Savvides SN, Gallardo R, Schymkowitz J, Rousseau F, Fox NC, Hopf C, De Strooper B, Chávez-Gutiérrez L. Alzheimer's-Causing Mutations Shift Aβ Length by Destabilizing γ-Secretase-Aβn Interactions. Cell. 2017 Jul 27;170(3):443-456.e14. PubMed. Correction.
79. Petit D, Fernández SG, Zoltowska KM, Enzlein T, Ryan NS, O'Connor A, Szaruga M, Hill E, Vandenberghe R, Fox NC, Chávez-Gutiérrez L. Aβ profiles generated by Alzheimer's disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Mol Psychiatry. 2022 Jun;27(6):2821-2832. Epub 2022 Apr 1 PubMed.
80. Liu L, Lauro BM, He A, Lee H, Bhattarai S, Wolfe MS, Bennett DA, Karch CM, Young-Pearse T, Dominantly Inherited Alzheimer Network (DIAN), Selkoe DJ. Identification of the Aβ37/42 peptide ratio in CSF as an improved Aβ biomarker for Alzheimer's disease. Alzheimers Dement. 2022 Mar 12; PubMed.
81. Schultz S, Liu L, Schultz A, Fitzpatrick C, Levin R, Bellier J-P, Shirzadi Z, Mathurin N, Chen C, Benzinger T, Day G, Farlow M, Gordon B, Hassenstab J, Jack C, Jucker M, Karch C, Lee J, Levin J, Perrin R, Schofield P, Xiong C, Johnson K, McDade E, Bateman R, Sperling R, Selkoe D, Chhatwal J, theDominantlyInheritedAlzheimer'sNetworkInvestigators. Functional variations in gamma-secretase activity are critical determinants of the clinical, biomarker, and cognitive progression of autosomal dominant Alzheimer's disease. 2023 Jul 25 10.1101/2023.07.04.547688 (version 2) bioRxiv.
82. Zhou R, Yang G, Guo X, Zhou Q, Lei J, Shi Y. Recognition of the amyloid precursor protein by human γ-secretase. Science. 2019 Feb 15;363(6428) Epub 2019 Jan 10 PubMed.
83. Dehury B, Somavarapu AK, Kepp KP. A computer-simulated mechanism of familial Alzheimer's disease: Mutations enhance thermal dynamics and favor looser substrate-binding to γ-secretase. J Struct Biol. 2020 Dec 1;212(3):107648. Epub 2020 Oct 21 PubMed.
84. Almeida MC, Eger SJ, He C, Audouard M, Nikitina A, Glasauer SM, Han D, Mejía-Cupajita B, Acosta-Uribe J, Villalba-Moreno ND, Littau JL, Elcheikhali M, Rivera EK, Carrettiero DC, Villegas-Lanau CA, Sepulveda-Falla D, Lopera F, Kosik KS. Single-nucleus RNA sequencing demonstrates an autosomal dominant Alzheimer's disease profile and possible mechanisms of disease protection. Neuron. 2024 Jun 5;112(11):1778-1794.e7. Epub 2024 Feb 27 PubMed.
85. Kim DY, Wertz MH, Gautam V, D'Avanzo C, Bhattacharyya R, Kovacs DM. The E280A presenilin mutation reduces voltage-gated sodium channel levels in neuronal cells. Neurodegener Dis. 2014;13(2-3):64-8. Epub 2013 Nov 5 PubMed.
86. Rojas-Charry L, Calero-Martinez S, Morganti C, Morciano G, Park K, Hagel C, Marciniak SJ, Glatzel M, Pinton P, Sepulveda-Falla D. Susceptibility to cellular stress in PS1 mutant N2a cells is associated with mitochondrial defects and altered calcium homeostasis. Sci Rep. 2020 Apr 15;10(1):6455. PubMed.
87. Han J, Park H, Maharana C, Gwon AR, Park J, Baek SH, Bae HG, Cho Y, Kim HK, Sul JH, Lee J, Kim E, Kim J, Cho Y, Park S, Palomera LF, Arumugam TV, Mattson MP, Jo DG. Alzheimer's disease-causing presenilin-1 mutations have deleterious effects on mitochondrial function. Theranostics. 2021;11(18):8855-8873. Epub 2021 Aug 17 PubMed.
88. Salcedo C, Wagner A, Andersen JV, Vinten KT, Waagepetersen HS, Schousboe A, Freude KK, Aldana BI. Downregulation of GABA Transporter 3 (GAT3) is Associated with Deficient Oxidative GABA Metabolism in Human Induced Pluripotent Stem Cell-Derived Astrocytes in Alzheimer's Disease. Neurochem Res. 2021 Oct;46(10):2676-2686. Epub 2021 Mar 12 PubMed.
89. Salcedo C, Pozo Garcia V, García-Adán B, Ameen AO, Gegelashvili G, Waagepetersen HS, Freude KK, Aldana BI. Increased glucose metabolism and impaired glutamate transport in human astrocytes are potential early triggers of abnormal extracellular glutamate accumulation in hiPSC-derived models of Alzheimer's disease. J Neurochem. 2024 May;168(5):822-840. Epub 2023 Dec 8 PubMed.
90. Xiao X, Liu H, Liu X, Zhang W, Zhang S, Jiao B. APP, PSEN1, and PSEN2 Variants in Alzheimer's Disease: Systematic Re-evaluation According to ACMG Guidelines. Front Aging Neurosci. 2021;13:695808. Epub 2021 Jun 18 PubMed.
91. Frederiksen HR, Holst B, Mau-Holzmann UA, Freude K, Schmid B. Generation of two isogenic iPSC lines with either a heterozygous or a homozygous E280A mutation in the PSEN1 gene. Stem Cell Res. 2019 Mar;35:101403. Epub 2019 Feb 7 PubMed.
92. Vallejo-Diez S, Fleischer A, Martín-Fernández JM, Sánchez-Gilabert A, Castresana M, Aguillón D, Villegas A, Mastronardi CA, Espinosa LG, Arcos-Burgos M, Del Pozo Á, Herrán E, Gainza E, Isaza-Ruget M, Lopera F, Bachiller D. Generation of one iPSC line (IMEDEAi006-A) from an early-onset familial Alzheimer's Disease (fAD) patient carrying the E280A mutation in the PSEN1 gene. Stem Cell Res. 2019 May;37:101440. Epub 2019 Apr 15 PubMed.

Other Citations

1. Sep 2022 conference news

Further Reading